Delivery Order SPE2DB20D9331-SPE2DB25FL1H0

Award Date 5/20/25
Potential Completion Date 6/11/25
Potential Value $146K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a ceiling value of $16,249.95 and a completion date of June 9, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of STELARA 90 MG/ML SYRINGEML, a prescription medication, with a ceiling value of $16,441.36 and a performance period through June 3, 2025. DMS Pharmaceutical Group Inc. has also been awarded a larger $499,999,999 Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of April 25, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract provides for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract has an ultimate completion date of April 30, 2025 and is not associated with a set-aside designation. DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML pharmaceutical products. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $8,220.68 and covers the delivery of STELARA 90 MG/ML SYRINGEML through April 15, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range of branded and generic prescription drugs, over-the-counter medications,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 1, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $16,441.36 contract is for the supply of Stelara 90 mg/ml syringes, with a performance period ending on May 12, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 firm fixed-price contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery orders for a comprehensive range of branded...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB25FL1H0
    Delivery Order

This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The contract is for the supply of STELARA 90 MG/ML SYRINGE/ML, a pharmaceutical product, with a ceiling value of $146,249.55 and a period of performance through June 11, 2025. DMS Pharmaceutical Group Inc. is a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites. The company holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs of military health facilities worldwide.

Generated 8/24/25, 12:46 AM